Literature DB >> 9804284

Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors.

R F Squires1, E Saederup.   

Abstract

Clozapine and several other antipsychotic/antidepressant drugs that fully or partially block GABA(A) receptors were tested at concentrations that reversed the inhibitory effect of 1 microM GABA on 35S-t-butylbicyclophosphorothionate ([35S]TBPS) binding to rat forebrain membranes only about 20-30%, here designated "core" fractions. Clozapine at 10 microM reverses 1 microM GABA 25+/-4.0% (n = 23) (its "core" fraction). Fourty three compounds were tested alone, and pairwise together with 10 microM Clozapine. The "core" fractions of some of the compounds yielded significant additive reversals together with 10 microM Clozapine, while others did not. A group of 14 compounds of which 7 are clinically effective antipsychotic drugs, including Chlorprothixene, Clomacran, Clopipazan, Fluotracen, Sulforidazine, Thioproperazine, and cis-Thiothixene, were statistically non-additive with 10 microM Clozapine, suggesting that all of these drugs selectively block the same core population of GABA(A) receptors as Clozapine. These non-additivities also suggest that Clozapine at 10 microM fully saturates a subset of GABA(A) receptors blocked by 1 microM GABA. Therefore, Clozapine probably blocks 2 or more types of GABA(A)receptors, but only half of the receptors that are sensitive to 1 microM GABA. A second group of 12 compounds of which 6 are clinically active antidepressant/antipsychotic drugs including Amoxapine, Clothiapine, Dibenzepine, Inkasan (Metralindole), Metiapine and Zimelidine were slightly, but significantly, additive with Clozapine suggesting that these compounds block most of Clozapine's core fraction, plus a small additional fraction. A third group consisted of ten compounds that yielded larger (R > 80) and statistically highly significant additivities with Clozapine. Complete additivity was obtained with Bathophenanthroline disulfonate, and Isocarboxazid, suggesting that they block GABA(A) receptors other than those blocked by 10 microM Clozapine. Seven "classical" GABA(A) receptor blockers, also tested at concentrations yielding 21 to 33% reversal alone, were all significantly additive with 10 microM Clozapine, but in no case was the additivity complete. The largest additivity was obtained with Pitrazepine (21%) and the smallest with Tubocurarine (9%). These results provide further support for the notion that selective blockade of the same subset of GABA(A) receptors may contribute to the clinical antipsychotic/antidepressant effects of Clozapine. The deltaB(opt) values for Clozapine are 50+/-1.7% and 26+/-2.6% (n = 3) in whole rat forebrain and cerebellum, respectively, confirming that clozapine-sensitive GABA(A) receptors are unevenly distributed in the brain. The sedative and anxiolytic properties of Clozapine and other antipsychotic drugs may be due to selective blockade of GABergic disinhibition at certain interneurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804284     DOI: 10.1023/a:1020796200769

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  18 in total

1.  The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon.

Authors:  W Wisden; D J Laurie; H Monyer; P H Seeburg
Journal:  J Neurosci       Date:  1992-03       Impact factor: 6.167

Review 2.  Which GABAA-receptor subtypes really occur in the brain?

Authors:  R M McKernan; P J Whiting
Journal:  Trends Neurosci       Date:  1996-04       Impact factor: 13.837

3.  Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

4.  Treatment of negative symptoms.

Authors:  W T Carpenter; D W Heinrichs; L D Alphs
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

5.  A steroid derivative, R 5135, antagonizes the GABA/benzodiazepine receptor interaction.

Authors:  P Hunt; S Clements-Jewery
Journal:  Neuropharmacology       Date:  1981-04       Impact factor: 5.250

6.  GABAA receptor blockers reverse the inhibitory effect of GABA on brain-specific [35S]TBPS binding.

Authors:  R F Squires; E Saederup
Journal:  Brain Res       Date:  1987-06-30       Impact factor: 3.252

7.  Methylene blue adjuvant therapy of schizophrenia.

Authors:  S I Deutsch; R B Rosse; B L Schwartz; M Fay-McCarthy; P B Rosenberg; K Fearing
Journal:  Clin Neuropharmacol       Date:  1997-08       Impact factor: 1.592

8.  Distribution, prevalence, and drug binding profile of gamma-aminobutyric acid type A receptor subtypes differing in the beta-subunit variant.

Authors:  D Benke; J M Fritschy; A Trzeciak; W Bannwarth; H Mohler
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

9.  GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits.

Authors:  J M Fritschy; H Mohler
Journal:  J Comp Neurol       Date:  1995-08-14       Impact factor: 3.215

10.  Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.

Authors:  E R Korpi; G Wong; H Lüddens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

View more
  13 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

2.  Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.

Authors:  Sampada A Shahane; Ruili Huang; David Gerhold; Ulrich Baxa; Christopher P Austin; Menghang Xia
Journal:  J Biomol Screen       Date:  2013-09-03

3.  Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  2000-12       Impact factor: 3.996

4.  The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.

Authors:  Kenjiro Yokota; Hideharu Tatebayashi; Tadashi Matsuo; Takashi Shoge; Haruhiko Motomura; Toshiyuki Matsuno; Akira Fukuda; Nobutada Tashiro
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 5.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1999-05       Impact factor: 3.996

Review 7.  Central GABAergic systems and depressive illness.

Authors:  G Tunnicliff; E Malatynska
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

8.  Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study.

Authors:  Nishant Goyal; Samir Kumar Praharaj; Pushpal Desarkar; Haque Nizamie
Journal:  Psychiatry Investig       Date:  2011-12-08       Impact factor: 2.505

9.  Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia.

Authors:  Yuka Sugawara Kikuchi; Wataru Sato; Keiichiro Ataka; Kiwamu Yagisawa; Yuki Omori; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-15       Impact factor: 2.570

10.  Clozapine response and pre-treatment EEG-is there some kind of relationship.

Authors:  Amresh Shrivastava; Megan Johnston; Nilesh Shah; Larry Stitt; Shivanshu Shrivastava; Avinash De Sousa
Journal:  Ind Psychiatry J       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.